On the public citation graph
Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox
0 signed · 282 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1001/jama.281.22.2127openalex-snapshot
Smallpox as a Biological Weapon
inferredcites →https://doi.org/10.1001/jama.289.24.3283openalex-snapshot
Myopericarditis Following Smallpox Vaccination Among Vaccinia-Naive US Military Personnel
inferredcites →https://doi.org/10.1001/jama.289.24.3295openalex-snapshot
Response to Smallpox Vaccine in Persons Immunized in the Distant Past
inferredcites →https://doi.org/10.1007/bf01641272openalex-snapshot
Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA
inferredcites →https://doi.org/10.1016/j.vaccine.2007.10.017openalex-snapshot
Clinical and immunologic responses to multiple doses of IMVAMUNE® (Modified Vaccinia Ankara) followed by Dryvax® challenge
inferredcites →https://doi.org/10.1016/j.vaccine.2008.11.079openalex-snapshot
Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax® in healthy vaccinia-naive adults
inferredcites →https://doi.org/10.1016/j.vaccine.2009.05.095openalex-snapshot
Modified vaccinia Ankara strains with identical coding sequences actually represent complex mixtures of viruses that determine the biological properties of each strain
inferredcites →https://doi.org/10.1016/j.vaccine.2014.08.022openalex-snapshot
Safety and immunogenicity of modified vaccinia Ankara as a smallpox vaccine in people with atopic dermatitis
inferredcites →https://doi.org/10.1016/j.vaccine.2015.04.062openalex-snapshot
Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response
inferredcites →https://doi.org/10.1037/e545972006-001openalex-snapshot
Smallpox Vaccination and Adverse Reactions: Guidance for Clinicians
inferredcites →https://doi.org/10.1037/e548252006-001openalex-snapshot
Vaccinia (Smallpox) Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2001
inferredcites →https://doi.org/10.1038/nature02331openalex-snapshot
Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox
inferredcites →https://doi.org/10.1038/s41541-020-0191-8openalex-snapshot
The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates
inferredcites →https://doi.org/10.1055/s-0028-1108143openalex-snapshot
MVA-Stufenimpfung gegen Pocken
inferredcites →https://doi.org/10.1056/nejm196911272812201openalex-snapshot
Complications of Smallpox Vaccination, 1968
inferredcites →https://doi.org/10.1056/nejm198011273032204openalex-snapshot
The Confirmation and Maintenance of Smallpox Eradication
inferredcites →https://doi.org/10.1073/pnas.0804985105openalex-snapshot
Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus
inferredcites →https://doi.org/10.1086/380906openalex-snapshot
Dose‐Dependent Neutralizing‐Antibody Responses to Vaccinia
inferredcites →https://doi.org/10.1086/423848openalex-snapshot
Induction of Human T Cell–Mediated Immune Responses after Primary and Secondary Smallpox Vaccination
inferredcites →https://doi.org/10.1089/hs.2017.0061openalex-snapshot
The De Novo Synthesis of Horsepox Virus: Implications for Biosecurity and Recommendations for Preventing the Reemergence of Smallpox
inferredcites →https://doi.org/10.1093/infdis/122.4.303openalex-snapshot
Complications of Smallpox Vaccination, 1968: Results of Ten Statewide Surveys
inferredcites →https://doi.org/10.1093/infdis/jis753openalex-snapshot
Safety, Immunogenicity, and Surrogate Markers of Clinical Efficacy for Modified Vaccinia Ankara as a Smallpox Vaccine in HIV-Infected Subjects
inferredcites →https://doi.org/10.1093/infdis/jit105openalex-snapshot
Safety and Immunogenicity of Modified Vaccinia Ankara in Hematopoietic Stem Cell Transplant Recipients: A Randomized, Controlled Trial
inferredcites →https://doi.org/10.1093/ofid/ofv040openalex-snapshot
Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
inferredcites →https://doi.org/10.1099/vir.0.010553-0openalex-snapshot
Evaluation of smallpox vaccines using variola neutralization
inferredcites →https://doi.org/10.1111/jdv.13797openalex-snapshot
Long‐term safety of replication‐defective smallpox vaccine (MVA‐BN) in atopic eczema and allergic rhinitis
inferredcites →https://doi.org/10.1128/jvi.79.12.7845-7851.2005openalex-snapshot
Modified Vaccinia Virus Ankara Protects Macaques against Respiratory Challenge with Monkeypox Virus
inferredcites →https://doi.org/10.1172/jci33940openalex-snapshot
Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection
inferredcites →https://doi.org/10.1371/journal.pone.0122653openalex-snapshot
Cardiac Safety of Modified Vaccinia Ankara for Vaccination against Smallpox in a Young, Healthy Study Population
inferredcites →https://doi.org/10.1371/journal.pone.0138348openalex-snapshot
A Multicenter, Open-Label, Controlled Phase II Study to Evaluate Safety and Immunogenicity of MVA Smallpox Vaccine (IMVAMUNE) in 18–40 Year Old Subjects with Diagnosed Atopic Dermatitis
inferredcites →https://doi.org/10.1371/journal.pone.0157335openalex-snapshot
A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects
inferredcites →https://doi.org/10.1371/journal.pone.0188453openalex-snapshot
Construction of an infectious horsepox virus vaccine from chemically synthesized DNA fragments
inferredcites →https://doi.org/10.1371/journal.pone.0195897openalex-snapshot
Immunogenicity and safety of three consecutive production lots of the non replicating smallpox vaccine MVA: A randomised, double blind, placebo controlled phase III trial
inferredcites →https://doi.org/10.3390/v12020138openalex-snapshot
Smallpox in the Post-Eradication Era
inferredcites →https://doi.org/10.3390/vaccines8010069openalex-snapshot
Plasmablast, Memory B Cell, CD4+ T Cell, and Circulating Follicular Helper T Cell Responses to a Non-Replicating Modified Vaccinia Ankara Vaccine
inferredcites →https://doi.org/10.4172/2157-2526.1000106openalex-snapshot
Likelihood of Smallpox Recurrence
inferredcites →https://doi.org/10.4269/ajtmh.1972.21.214openalex-snapshot
A Prospective Study of Serum Antibody and Protection Against Smallpox
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4572849openalex-extracted
Immunogenicity and Reactogenicity of Modified Vaccinia Ankara Pre-Exposure Vaccination Against Mpox According to Previous Smallpox Vaccine Exposure
inferred← citeshttps://doi.org/10.1001/jama.2022.18320openalex-snapshot
Human Monkeypox Virus Infection in the Immediate Period After Receiving Modified Vaccinia Ankara Vaccine
inferred← citeshttps://doi.org/10.1002/ana.26473openalex-snapshot
An Overview of Monkeypox Virus and Its Neuroinvasive Potential
inferred← citeshttps://doi.org/10.1002/cpdd.1275openalex-snapshot
Anti‐Monkeypox Infection Approaches: From Prevention to Therapeutic Lines
inferred← citeshttps://doi.org/10.1002/hsr2.70069openalex-snapshot
Effectiveness of a single dose of JYNNEOS vaccine in real world: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1002/jmv.28229openalex-snapshot
Monkeypox treatment: Current evidence and future perspectives
inferred← citeshttps://doi.org/10.1002/jmv.28306openalex-snapshot
Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies
inferred← citeshttps://doi.org/10.1002/jmv.28643openalex-snapshot
Smallpox vaccination‐elicited antibodies cross‐neutralize 2022‐Monkeypox virus Clade II
inferred← citeshttps://doi.org/10.1002/jmv.29140openalex-snapshot
Evaluation and comparison of immune responses induced by two Mpox mRNA vaccine candidates in mice
inferred← citeshttps://doi.org/10.1002/jmv.29407openalex-snapshot
Characterizing the acute antibody response of monkeypox and MVA‐BN vaccine following an Australian outbreak
inferred← citeshttps://doi.org/10.1002/mco2.70525openalex-snapshot
Monkeypox Virus: Epidemiology, Virology, Diagnosis, Vaccine, and Therapeutics
inferred← citeshttps://doi.org/10.1002/rmv.2392openalex-snapshot
Monkeypox: An international epidemic
inferred← citeshttps://doi.org/10.1002/rmv.2489openalex-snapshot
The 2022 monkeypox outbreak 1 year on: The 5 Ws
inferred← citeshttps://doi.org/10.1002/wnan.1681openalex-snapshot
Advancements in protein nanoparticle vaccine platforms to combat infectious disease
inferred← citeshttps://doi.org/10.1007/978-3-031-57165-7_18openalex-snapshot
Current Status of Vaccine Development for Monkeypox Virus
inferred← citeshttps://doi.org/10.1007/s00203-025-04695-4openalex-snapshot
Monkey pox (Mpox): pathogenesis, genetic shifts, vaccination strategies and clinical insights
inferred← citeshttps://doi.org/10.1007/s00705-023-05808-4openalex-snapshot
A systematic review to identify novel clinical characteristics of monkeypox virus infection and therapeutic and preventive strategies to combat the virus
inferred← citeshttps://doi.org/10.1007/s11904-023-00661-1openalex-snapshot
Mpox and HIV: a Narrative Review
inferred← citeshttps://doi.org/10.1007/s12326-023-00553-6openalex-snapshot
Mpox – ein neuer Name für eine alte Krankheit oder doch alles anders?
inferred← citeshttps://doi.org/10.1007/s13337-026-00981-xopenalex-snapshot
An updated review of monkeypox virus infection's global prevalence and health risks with supporting treatment and diagnosis
inferred← citeshttps://doi.org/10.1007/s40264-026-01657-7openalex-snapshot
Maternal and Pediatric Use of Vaccines for Mpox: A Living Systematic Review and Meta-analysis of Safety and Effectiveness
inferred← citeshttps://doi.org/10.1007/s40506-022-00260-5openalex-snapshot
Mpox: Special Considerations in the Immunocompromised Host
inferred← citeshttps://doi.org/10.1007/s44197-025-00432-8openalex-snapshot
Safety and Efficacy of Repurposed Smallpox Vaccines Against Mpox: A Critical Review of ACAM2000, JYNNEOS, and LC16
inferred← citeshttps://doi.org/10.1016/b978-0-12-809633-8.21545-8openalex-snapshot
Variola and Monkeypox Viruses (Poxviridae)
inferred← citeshttps://doi.org/10.1016/b978-0-323-79058-1.00055-4openalex-snapshot
Smallpox and Vaccinia
inferred← citeshttps://doi.org/10.1016/b978-0-323-79058-1.00210-3openalex-snapshot
Vaccines to Prevent Mpox
inferred← citeshttps://doi.org/10.1016/b978-0-323-82763-8.00164-3openalex-snapshot
Monkeypox and Other Poxviruses
inferred← citeshttps://doi.org/10.1016/b978-0-443-22123-1.00019-3openalex-snapshot
Immunoinformatics and monkeypox virus vaccines
inferred← citeshttps://doi.org/10.1016/bs.ircmb.2023.05.003openalex-snapshot
Armored modified vaccinia Ankara in cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.bj.2024.100746openalex-snapshot
“Mpox in MSM: Tackling stigma, minimizing risk factors, exploring pathogenesis, and treatment approaches”
inferred← citeshttps://doi.org/10.1016/j.celrep.2023.112407openalex-snapshot
T helper 1 effector memory CD4+ T cells protect the skin from poxvirus infection
inferred← citeshttps://doi.org/10.1016/j.celrep.2023.113609openalex-snapshot
Long-lasting humoral and cellular memory immunity to vaccinia virus Tiantan provides pre-existing immunity against mpox virus in Chinese population
inferred← citeshttps://doi.org/10.1016/j.chom.2024.10.014openalex-snapshot
mRNA vaccines: A promising platform for safer, more effective next-generation Orthopoxvirus immunization
inferred← citeshttps://doi.org/10.1016/j.clim.2022.109108openalex-snapshot
The resurgence of a neglected orthopoxvirus: Immunologic and clinical aspects of monkeypox virus infections over the past six decades
inferred← citeshttps://doi.org/10.1016/j.disamonth.2026.102130openalex-snapshot
Monkeypox (mpox) vaccine
inferred← citeshttps://doi.org/10.1016/j.ebiom.2025.105622openalex-snapshot
Development and validation of a quantitative Orthopoxvirus immunoassay to evaluate and differentiate serological responses to Mpox infection and vaccination
inferred← citeshttps://doi.org/10.1016/j.eclinm.2023.102420openalex-snapshot
Immunogenicity and reactogenicity of modified vaccinia Ankara pre-exposure vaccination against mpox according to previous smallpox vaccine exposure and HIV infection: prospective cohort study
inferred← citeshttps://doi.org/10.1016/j.ijbiomac.2026.150733openalex-snapshot
MPXV protein scaffold cum antigen-based macromolecular multi-antigen displaying next-generation vaccine, providing coordinated humoral and cellular response
inferred← citeshttps://doi.org/10.1016/j.ijsu.2022.106869openalex-snapshot
Monkeypox vaccines and vaccination strategies: Current knowledge and advances. An update – Correspondence
inferred← citeshttps://doi.org/10.1016/j.jim.2024.113787openalex-snapshot
Plaque reduction neutralization test for smallpox vaccines: Laboratory optimization and validation method for immunogenicity assessment
inferred← citeshttps://doi.org/10.1016/j.jinf.2026.106769openalex-snapshot
All-cause mortality within seven days of COVID-19 vaccination: A matched cohort and self-controlled case series study in Lombardy, Italy
inferred← citeshttps://doi.org/10.1016/j.jiph.2023.04.001openalex-snapshot
Mpox: Risks and approaches to prevention
inferred← citeshttps://doi.org/10.1016/j.jiph.2024.04.002openalex-snapshot
Age-related antibody response to Orthopoxviruses and implications for public health measures: Insights from a South Korean study
inferred← citeshttps://doi.org/10.1016/j.jmb.2023.168173openalex-snapshot
Highly Attenuated Poxvirus-Based Vaccines Against Emerging Viral Diseases
inferred← citeshttps://doi.org/10.1016/j.lanepe.2024.101020openalex-snapshot
Impact of vaccination with third generation modified vaccinia Ankara and sexual behaviour on mpox incidence in men who have sex with men: analysis among participants of the ANRS-174 DOXYVAC trial
inferred← citeshttps://doi.org/10.1016/j.medcle.2023.01.005openalex-snapshot
Vaccines against monkeypox
inferred← citeshttps://doi.org/10.1016/j.medcli.2023.01.001openalex-snapshot
Vacunas frente a la viruela del mono (monkeypox)
inferred← citeshttps://doi.org/10.1016/j.micpath.2023.106027openalex-snapshot
Monkeypox virus: A review
inferred← citeshttps://doi.org/10.1016/j.microb.2025.100330openalex-snapshot
Current trends in diagnostics, biomarker identification, and drug discovery targeting Monkeypox (Mpox)
inferred← citeshttps://doi.org/10.1016/j.smim.2020.101430openalex-snapshot
New viral vectors for infectious diseases and cancer
inferred← citeshttps://doi.org/10.1016/j.supmat.2024.100071openalex-snapshot
WITHDRAWN: Monkeypox: A Timely Update on the Global Outbreak, Transmission, Viral Replication, Vaccination and Clinical Strategies
inferred← citeshttps://doi.org/10.1016/j.vaccine.2020.01.058openalex-snapshot
A randomized phase II trial to compare safety and immunogenicity of the MVA-BN smallpox vaccine at various doses in adults with a history of AIDS
inferred← citeshttps://doi.org/10.1016/j.vaccine.2020.07.018openalex-snapshot
Short-term and longer-term protective immune responses generated by subunit vaccination with smallpox A33, B5, L1 or A27 proteins adjuvanted with aluminum hydroxide and CpG in mice challenged with vaccinia virus
inferred← citeshttps://doi.org/10.1016/j.vaccine.2020.08.050openalex-snapshot
The Brighton Collaboration standardized template for collection of key information for risk/benefit assessment of a Modified Vaccinia Ankara (MVA) vaccine platform
inferred← citeshttps://doi.org/10.1016/j.vaccine.2022.10.078openalex-snapshot
Serological responses to the MVA-based JYNNEOS monkeypox vaccine in a cohort of participants from the Democratic Republic of Congo
inferred← citeshttps://doi.org/10.1016/j.vaccine.2023.12.066openalex-snapshot
JYNNEOS™ effectiveness as post-exposure prophylaxis against mpox: Challenges using real-world outbreak data
inferred← citeshttps://doi.org/10.1016/j.vaccine.2023.12.068openalex-snapshot
Prospective monitoring of adverse events following vaccination with Modified vaccinia Ankara - Bavarian Nordic (MVA-BN) administered to a Canadian population at risk of Mpox: A Canadian Immunization Research Network study
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.03.011openalex-snapshot
Safety and immunogenicity of a novel trivalent recombinant MVA-based equine encephalitis virus vaccine: A Phase 1 clinical trial
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.05.017openalex-snapshot
Serologic responses to the MVA-based JYNNEOS mpox vaccine in a cohort of participants from the District of Columbia (D.C.)
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.05.035openalex-snapshot
Effectiveness of JYNNEOS vaccine against symptomatic mpox disease in adult men in Los Angeles County, August 29, 2022 to January 1, 2023
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.06.021openalex-snapshot
Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.126409openalex-snapshot
MVA-BN vaccine effectiveness: A systematic review of real-world evidence in outbreak settings
inferred← citeshttps://doi.org/10.1016/j.vaccine.2024.126521openalex-snapshot
A Brighton collaboration standardized template with key considerations for a benefit/risk assessment for a viral vector vaccine based on a non-replicating modified vaccinia virus Ankara viral vector
inferred← citeshttps://doi.org/10.1016/j.vaccine.2025.127492openalex-snapshot
Development of a live-attenuated vaccine challenge model of Yersinia pestis in humans: Expert consultation on clinical trial considerations, January 2025
inferred← citeshttps://doi.org/10.1016/j.vaccine.2025.127959openalex-snapshot
Evaluation of the safety and immunogenicity of two fractional intradermal regimens of MVA-BN compared to standard dose vaccination
inferred← citeshttps://doi.org/10.1016/j.xcrm.2021.100209openalex-snapshot
Heterologous arenavirus vector prime-boost overrules self-tolerance for efficient tumor-specific CD8 T cell attack
inferred← citeshttps://doi.org/10.1016/j.ymthe.2021.10.008openalex-snapshot
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection
inferred← citeshttps://doi.org/10.1016/s1473-3099(22)00574-6openalex-snapshot
Prevention of monkeypox with vaccines: a rapid review
inferred← citeshttps://doi.org/10.1016/s1473-3099(23)00057-9openalex-snapshot
Effectiveness of one dose of MVA–BN smallpox vaccine against mpox in England using the case-coverage method: an observational study
inferred← citeshttps://doi.org/10.1016/s1473-3099(23)00270-0openalex-snapshot
Early evaluation of the safety, reactogenicity, and immune response after a single dose of modified vaccinia Ankara–Bavaria Nordic vaccine against mpox in children: a national outbreak response
inferred← citeshttps://doi.org/10.1016/s1473-3099(23)00294-3openalex-snapshot
Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy
inferred← citeshttps://doi.org/10.1016/s1473-3099(25)00018-0openalex-snapshot
Safety and effectiveness of MVA-BN vaccination against mpox in at-risk individuals in Germany (SEMVAc and TEMVAc): a combined prospective and retrospective cohort study
inferred← citeshttps://doi.org/10.1016/s1473-3099(25)00282-8openalex-snapshot
Mpox vaccines attenuate disease—but evidence and equity gaps remain
inferred← citeshttps://doi.org/10.1016/s1473-3099(26)00001-0openalex-snapshot
Immunogenicity and safety of MVA-BN vaccine administered 5 years after a two-dose primary series in DR Congo: a prospective cohort study
inferred← citeshttps://doi.org/10.1016/s1773-035x(24)00300-9openalex-snapshot
Vaccination contre le Mpox : état des lieux et perspectives
inferred← citeshttps://doi.org/10.1038/d41591-022-00077-1openalex-snapshot
A prospective national cohort evaluating ring MVA vaccination as post-exposure prophylaxis for monkeypox
inferred← citeshttps://doi.org/10.1038/s41392-022-01215-4openalex-snapshot
Monkeypox: epidemiology, pathogenesis, treatment and prevention
inferred← citeshttps://doi.org/10.1038/s41392-023-01408-5openalex-snapshot
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases
inferred← citeshttps://doi.org/10.1038/s41422-023-00792-5openalex-snapshot
Polyvalent mRNA vaccination elicited potent immune response to monkeypox virus surface antigens
inferred← citeshttps://doi.org/10.1038/s41467-023-38514-5openalex-snapshot
Vaccinia E5 is a major inhibitor of the DNA sensor cGAS
inferred← citeshttps://doi.org/10.1038/s41467-023-40430-7openalex-snapshot
Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques
inferred← citeshttps://doi.org/10.1038/s41467-024-48180-wopenalex-snapshot
Predicting vaccine effectiveness for mpox
inferred← citeshttps://doi.org/10.1038/s41467-025-62681-2openalex-snapshot
Efficacy of modified-vaccinia Ankara vaccine as pre- and post-exposure prophylaxis against monkeypox sexual transmission in non-human primate model
inferred← citeshttps://doi.org/10.1038/s41541-020-00265-5openalex-snapshot
Epicutaneous immunization with modified vaccinia Ankara viral vectors generates superior T cell immunity against a respiratory viral challenge
inferred← citeshttps://doi.org/10.1038/s41541-020-0191-8openalex-snapshot
The vaccinia virus based Sementis Copenhagen Vector vaccine against Zika and chikungunya is immunogenic in non-human primates
inferred← citeshttps://doi.org/10.1038/s41541-022-00436-6openalex-snapshot
Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates
inferred← citeshttps://doi.org/10.1038/s41541-022-00542-5openalex-snapshot
Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
inferred← citeshttps://doi.org/10.1038/s41541-024-00842-yopenalex-snapshot
MVA-based vaccines are protective against lethal eastern equine encephalitis virus aerosol challenge in cynomolgus macaques
inferred← citeshttps://doi.org/10.1038/s41577-023-00853-1openalex-snapshot
Assessing the generation of tissue resident memory T cells by vaccines
inferred← citeshttps://doi.org/10.1038/s41579-020-00441-3openalex-snapshot
Prospects for SARS-CoV-2 diagnostics, therapeutics and vaccines in Africa
inferred← citeshttps://doi.org/10.1038/s41591-022-02090-wopenalex-snapshot
Low levels of monkeypox virus-neutralizing antibodies after MVA-BN vaccination in healthy individuals
inferred← citeshttps://doi.org/10.1038/s41591-023-02229-3openalex-snapshot
Real-world effectiveness of a single dose of mpox vaccine in males
inferred← citeshttps://doi.org/10.1038/s41598-023-32060-2openalex-snapshot
Preclinical development of a first-in-class vaccine encoding HER2, Brachyury and CD40L for antibody enhanced tumor eradication
inferred← citeshttps://doi.org/10.1038/s43856-024-00443-9openalex-snapshot
Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
inferred← citeshttps://doi.org/10.1056/nejmc2001156openalex-snapshot
A Modified Vaccine against Smallpox
inferred← citeshttps://doi.org/10.1080/14760584.2024.2397006openalex-snapshot
Vaccines against mpox: MVA-BN and LC16m8
inferred← citeshttps://doi.org/10.1080/14760584.2026.2708197openalex-snapshot
ACAM2000 vaccine safety and immunogenicity considerations for smallpox and mpox
inferred← citeshttps://doi.org/10.1080/17843286.2026.2706157openalex-snapshot
Mpox vaccination in Belgium: clinical guidance for implementation readiness
inferred← citeshttps://doi.org/10.1080/2162402x.2022.2098657openalex-snapshot
Synergistic antitumor response with recombinant modified virus Ankara armed with CD40L and CD137L against peritoneal carcinomatosis
inferred← citeshttps://doi.org/10.1080/21645515.2020.1704575openalex-snapshot
Human Vaccines & Immunotherapeutics: news
inferred← citeshttps://doi.org/10.1080/21645515.2023.2242219openalex-snapshot
An open-label, non-randomized study investigating the safety and efficacy of smallpox vaccine, LC16, as post-exposure prophylaxis for mpox
inferred← citeshttps://doi.org/10.1080/21645515.2024.2384189openalex-snapshot
Equivalence of freeze-dried and liquid-frozen formulations of MVA-BN as smallpox and mpox vaccine
inferred← citeshttps://doi.org/10.1093/aje/kwae350openalex-snapshot
Emulating target trials of postexposure vaccines using observational data
inferred← citeshttps://doi.org/10.1093/bmb/ldad002openalex-snapshot
Monkeypox: a review of the 2022 outbreak
inferred← citeshttps://doi.org/10.1093/cid/ciad645openalex-snapshot
Effectiveness of Modified Vaccinia Ankara-Bavaria Nordic Vaccination in a Population at High Risk of Mpox: A Spanish Cohort Study
inferred← citeshttps://doi.org/10.1093/infdis/jiaa460openalex-snapshot
Broad Antibody and Cellular Immune Response From a Phase 2 Clinical Trial With a Novel Multivalent Poxvirus-Based Respiratory Syncytial Virus Vaccine
inferred← citeshttps://doi.org/10.1093/infdis/jiac455openalex-snapshot
One- and Two-Dose Vaccinations With Modified Vaccinia Ankara-Bavarian Nordic Induce Durable B-Cell Memory Responses Comparable to Replicating Smallpox Vaccines
inferred← citeshttps://doi.org/10.1093/infdis/jiad052openalex-snapshot
Monkeypox Virus Cross-Neutralizing Antibodies in Clinical Trial Participants Vaccinated With Modified Vaccinia Virus Ankara Encoding Middle East Respiratory Syndrome–Coronavirus Spike Protein
inferred← citeshttps://doi.org/10.1093/infdis/jiae515openalex-snapshot
Monkeypox Virus Infection Stimulates a More Robust and Durable Neutralizing Antibody Response Compared to Modified Vaccinia Virus Ankara Vaccination
inferred← citeshttps://doi.org/10.1093/jimmun/vkae031openalex-snapshot
Characterization and comparison of immunity against MPXV for individuals infected with MPXV or vaccinated with modified vaccinia Ankara vaccines
inferred← citeshttps://doi.org/10.1093/ofid/ofaa111openalex-snapshot
Contact Transmission of Vaccinia to an Infant Diagnosed by Viral Culture and Metagenomic Sequencing
inferred← citeshttps://doi.org/10.1093/ofid/ofac310openalex-snapshot
Monkeypox: A Contemporary Review for Healthcare Professionals
inferred← citeshttps://doi.org/10.1093/ofid/ofad632openalex-snapshot
A Case of Sustained Viral Shedding of Mpox With Ocular Involvement Resulting in Vision Loss
inferred← citeshttps://doi.org/10.1093/ofid/ofaf536openalex-snapshot
Antibody Responses are Sustained 2 Years Post-Mpox Infection but not Following Modified Vaccinia Ankara–Bavarian Nordic Vaccination
inferred← citeshttps://doi.org/10.1093/trstmh/trac082openalex-snapshot
Monkeypox is an outbreak of international concern
inferred← citeshttps://doi.org/10.1097/coh.0000000000001013openalex-snapshot
Pro/con: vaccination and waning immunity – presents contrasting perspectives on the durability of vaccine-induced protection and the potential need for booster strategies
inferred← citeshttps://doi.org/10.1097/ms9.0000000000003558openalex-snapshot
Potential of MRNA vaccines for mpox prevention: current evidence and future directions
inferred← citeshttps://doi.org/10.1097/ms9.0000000000004534openalex-snapshot
The emergence of Clade IIb and Ib mpox viruses: a state-of-the-art review
inferred← citeshttps://doi.org/10.1097/qad.0000000000003733openalex-snapshot
Viral blips and virologic failures following mpox vaccination with MVA-BN among people with HIV
inferred← citeshttps://doi.org/10.1099/jgv.0.002157openalex-snapshot
Immunogenicity of a trivalent haemorrhagic fever vaccine candidate against Sudan virus, Marburg virus and Lassa virus in an mpox vaccine
inferred← citeshttps://doi.org/10.1101/2021.07.24.453449openalex-snapshot
Heat-inactivated modified vaccinia virus Ankara boosts Th1-biased cellular and humoral immune responses as a vaccine adjuvant by activating the STING-mediated cytosolic DNA-sensing pathway
inferred← citeshttps://doi.org/10.1101/2022.05.26.22273379openalex-snapshot
Clinical characterization of human monkeypox infections in the Democratic Republic of the Congo
inferred← citeshttps://doi.org/10.1101/2022.05.27.493507openalex-snapshot
Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert tumor microenvironment and confers resistance to immunotherapy
inferred← citeshttps://doi.org/10.1101/2022.07.26.22277958openalex-snapshot
Synthetic modified vaccinia Ankara vaccines confer potent monkeypox immunity in non-human primates and healthy adults
inferred← citeshttps://doi.org/10.1101/2022.08.03.22278233openalex-snapshot
Breakthrough infections after post-exposure vaccination against Monkeypox
inferred← citeshttps://doi.org/10.1101/2022.09.07.22279689openalex-snapshot
Single and 2-dose vaccinations with MVA-BN ® induce durable B cell memory responses in healthy volunteers that are comparable to older generation replicating smallpox vaccines
inferred← citeshttps://doi.org/10.1101/2022.09.25.509429openalex-snapshot
Innate–adaptive IFN cross-talk reprograms myeloid and T cells for antitumor immunity with a second-generation recombinant MVA
inferred← citeshttps://doi.org/10.1101/2023.01.06.23284258openalex-snapshot
“Novel Clinical Manifestations of Human Monkeypox Virus Infection and Current Therapeutic and Preventive Strategies: A Systematic Review “
inferred← citeshttps://doi.org/10.1101/2023.03.07.23286701openalex-snapshot
Mpox vaccine and infection-driven human immune signatures
inferred← citeshttps://doi.org/10.1101/2023.05.03.23289471openalex-snapshot
Defining and emulating target trials of the effects of postexposure vaccination using observational data
inferred← citeshttps://doi.org/10.1101/2023.05.30.23290712openalex-snapshot
Reduction in the risk of mpox infection after MVA-BN vaccination in individuals on HIV pre-exposure prophylaxis: a Spanish cohort study
inferred← citeshttps://doi.org/10.1101/2023.10.04.23296566openalex-snapshot
Effectiveness of one dose of MVA-BN vaccine against mpox infection in males in Ontario, Canada: A target trial emulation
inferred← citeshttps://doi.org/10.1101/2024.08.28.24312561openalex-snapshot
JYNNEOS vaccination induced short-lived neutralizing antibody responses to monkeypox virus in naïve individuals
inferred← citeshttps://doi.org/10.1101/2025.06.06.25329130openalex-snapshot
MVA-BN third-dose 5 years after primary; Democratic Republic of the Congo
inferred← citeshttps://doi.org/10.1111/bcp.15830openalex-snapshot
Adverse reactions following MPox (monkeypox) vaccination: An overview from the Dutch and global adverse event reporting systems
inferred← citeshttps://doi.org/10.1111/jdv.18622openalex-snapshot
Monkeypox vaccine: Special considerations for dermatologic patients
inferred← citeshttps://doi.org/10.1128/jvi.00253-25openalex-snapshot
The two-dose MVA-BN mpox vaccine induces a nondurable and low avidity MPXV-specific antibody response
inferred← citeshttps://doi.org/10.1128/jvi.02260-20openalex-snapshot
COVID-19 Vaccine Candidates Based on Modified Vaccinia Virus Ankara Expressing the SARS-CoV-2 Spike Protein Induce Robust T- and B-Cell Immune Responses and Full Efficacy in Mice
inferred← citeshttps://doi.org/10.1136/bmj-2023-078243openalex-snapshot
Effectiveness of modified vaccinia Ankara-Bavarian Nordic vaccine against mpox infection: emulation of a target trial
inferred← citeshttps://doi.org/10.1136/bmjopen-2026-120064openalex-snapshot
Examining the immune response of participants receiving Modified Vaccinia Ankara vaccine in Africa (MpoxVax AFRIVAC): a prospective cohort study – protocol
inferred← citeshttps://doi.org/10.1136/bmjph-2023-000620openalex-snapshot
Evaluation of pre-exposure vaccine effectiveness against mpox during the 2022–2023 mpox outbreak in the Madrid region (Spain): a test-negative design
inferred← citeshttps://doi.org/10.1136/jitc-2020-001586openalex-snapshot
Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory
inferred← citeshttps://doi.org/10.1136/jitc-2023-006702openalex-snapshot
Intraperitoneal administration of a modified vaccinia virus Ankara confers single-chain interleukin-12 expression to the omentum and achieves immune-mediated efficacy against peritoneal carcinomatosis
inferred← citeshttps://doi.org/10.1136/jitc-2023-006718openalex-snapshot
Vector Aided Microenvironment programming (VAMP): reprogramming the TME with MVA virus expressing IL-12 for effective antitumor activity
inferred← citeshttps://doi.org/10.1146/annurev-immunol-101320-020220openalex-snapshot
The Multifaceted Role of Tissue-Resident Memory T Cells
inferred← citeshttps://doi.org/10.1172/jci153437openalex-snapshot
Tumor-intrinsic PRC2 inactivation drives a context-dependent immune-desert microenvironment and is sensitized by immunogenic viruses
inferred← citeshttps://doi.org/10.1172/jci167632openalex-snapshot
Vaxxing to elimination: smallpox vaccines as tools to fight mpox
inferred← citeshttps://doi.org/10.1177/25151355251314339openalex-snapshot
Current advances and challenges in mpox vaccine development: a global landscape
inferred← citeshttps://doi.org/10.1186/s12879-022-07900-7openalex-snapshot
Human monkeypox: a comparison of the characteristics of the new epidemic to the endemic disease
inferred← citeshttps://doi.org/10.12788/cutis.0502openalex-snapshot
Acral Papulovesicular Eruption in a Soldier Following Smallpox Vaccination
inferred← citeshttps://doi.org/10.1360/tb-2023-1092openalex-snapshot
Advancements in the development of mRNA vaccine against monkeypox virus
inferred← citeshttps://doi.org/10.1371/journal.pntd.0010384openalex-snapshot
Clinical characterization and placental pathology of mpox infection in hospitalized patients in the Democratic Republic of the Congo
inferred← citeshttps://doi.org/10.1371/journal.ppat.1009215openalex-snapshot
Injection site vaccinology of a recombinant vaccinia-based vector reveals diverse innate immune signatures
inferred← citeshttps://doi.org/10.15581/10171/69184openalex-snapshot
Evaluation of Modified Vaccinia virus Ankara based locoregional immunotherapy in peritoneal carcinomatosis models
inferred← citeshttps://doi.org/10.15585/mmwr.mm7122e1openalex-snapshot
Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022
inferred← citeshttps://doi.org/10.15585/mmwr.mm7220a4openalex-snapshot
Effectiveness of JYNNEOS Vaccine Against Diagnosed Mpox Infection — New York, 2022
inferred← citeshttps://doi.org/10.20892/j.issn.2095-3941.2023.0202openalex-snapshot
Preclinical and clinical trials of oncolytic vaccinia virus in cancer immunotherapy: a comprehensive review
inferred← citeshttps://doi.org/10.2105/ajph.2021.306495openalex-snapshot
An Unnecessary Gift for COVID-19 Vaccines and Therapeutics: The Medical Countermeasure Priority Review Voucher
inferred← citeshttps://doi.org/10.21070/ijhsm.v1i2.24openalex-snapshot
A Review: Diagnosis and Treatment of Monkeypox Patients
inferred← citeshttps://doi.org/10.21203/rs.3.rs-1976861/v2openalex-snapshot
Effectiveness of a single-dose Modified Vaccinia Ankara in Human Monkeypox: an observational study
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2156493/v1openalex-snapshot
Level of Knowledge regarding Monkeypox among Peruvian Physicians during the 2022 Outbreak: A Cross-Sectional Study
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2795799/v1openalex-snapshot
Perceptions and Intention to get vaccinated against Mpox among the LGTBIQ+ Community during the 2022 outbreak: A Cross-Sectional Study in Peru
inferred← citeshttps://doi.org/10.2139/ssrn.4939172openalex-snapshot
Plaque Reduction Neutralization Test for Smallpox Vaccines: Laboratory Optimization and Validation Method for Immunogenicity Assessment
inferred← citeshttps://doi.org/10.22541/au.168846306.66701439/v1openalex-snapshot
Recent Advances in Monkeypox (Mpox): Characterization, Diagnosis, and Therapeutics - A Multidimensional Review
inferred← citeshttps://doi.org/10.23736/s2784-8671.25.08332-xopenalex-snapshot
Cutaneous Mpox: an epidemiological, clinical, diagnostic and therapeutic review of the dermatologic pandemic of the decade
inferred← citeshttps://doi.org/10.24075/brsmu.2023.010openalex-snapshot
Comparison of the oncolytic activity of recombinant vaccinia virus strains LIVP-RFP and MVA-RFP against solid tumors
inferred← citeshttps://doi.org/10.24075/vrgmu.2023.010openalex-snapshot
Sravnenie onkoliticheskoj aktivnosti rekombinantnyh shtammov virusa ospovakciny LIVP-RFP i MVA-RFP v otnoshenii solidnyh opuholej
inferred← citeshttps://doi.org/10.2807/1560-7917.es.2022.27.48.2200894openalex-snapshot
Severe mpox (formerly monkeypox) disease in five patients after recent vaccination with MVA-BN vaccine, Belgium, July to October 2022
inferred← citeshttps://doi.org/10.2807/1560-7917.es.2022.27.50.2200882openalex-snapshot
Outcomes of post-exposure vaccination by modified vaccinia Ankara to prevent mpox (formerly monkeypox): a retrospective observational study in Lyon, France, June to August 2022
inferred← citeshttps://doi.org/10.2807/1560-7917.es.2023.28.12.2200772openalex-snapshot
Mpox outbreak in the Netherlands, 2022: public health response, characteristics of the first 1,000 cases and protection of the first-generation smallpox vaccine
inferred← citeshttps://doi.org/10.2807/1560-7917.es.2024.29.21.2300608openalex-snapshot
Factors potentially contributing to the decline of the mpox outbreak in the Netherlands, 2022 and 2023
inferred← citeshttps://doi.org/10.30699/ijmm.16.6.607openalex-snapshot
Monkeypox: A Re-emerging Infectious Disease
inferred← citeshttps://doi.org/10.3201/eid3102.241300openalex-snapshot
Short-Lived Neutralizing Antibody Responses to Monkeypox Virus in Smallpox Vaccine–Naive Persons after JYNNEOS Vaccination
inferred← citeshttps://doi.org/10.32440/ar.2020.137.02.rev18openalex-snapshot
Towards the spanish vaccine against SARS-CoV-2, responsible for the pandemic Covid-19
inferred← citeshttps://doi.org/10.33442/vt202158openalex-snapshot
Smallpox and Other Orthopoxvirus Diseases
inferred← citeshttps://doi.org/10.3389/av.2025.14597openalex-snapshot
Insights into poxviruses: virology and vaccines
inferred← citeshttps://doi.org/10.3389/fcimb.2023.1196699openalex-snapshot
The prospective outcome of the monkeypox outbreak in 2022 and characterization of monkeypox disease immunobiology
inferred← citeshttps://doi.org/10.3389/fimmu.2020.01959openalex-snapshot
Combating COVID-19: MVA Vector Vaccines Applied to the Respiratory Tract as Promising Approach Toward Protective Immunity in the Lung
inferred← citeshttps://doi.org/10.3389/fimmu.2020.02096openalex-snapshot
Modulation of Cell Surface Receptor Expression by Modified Vaccinia Virus Ankara in Leukocytes of Healthy and HIV-Infected Individuals
inferred← citeshttps://doi.org/10.3389/fimmu.2020.598847openalex-snapshot
A Monovalent and Trivalent MVA-Based Vaccine Completely Protects Mice Against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenge
inferred← citeshttps://doi.org/10.3389/fimmu.2021.645210openalex-snapshot
Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response
inferred← citeshttps://doi.org/10.3389/fimmu.2021.784813openalex-snapshot
The Route of Vaccine Administration Determines Whether Blood Neutrophils Undergo Long-Term Phenotypic Modifications
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1277447openalex-snapshot
Whole genome sequencing of recombinant viruses obtained from co-infection and superinfection of Vero cells with modified vaccinia virus ankara vectored influenza vaccine and a naturally occurring cowpox virus
inferred← citeshttps://doi.org/10.3389/fimmu.2024.1445209openalex-snapshot
Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1771410openalex-snapshot
MVA-Spike encoding the A subunit of dmLT safely enhances systemic and mucosal immune responses
inferred← citeshttps://doi.org/10.3389/fmicb.2025.1572706openalex-snapshot
Design and construction of a fast synthetic modified vaccinia virus Ankara reverse genetics system for advancing vaccine development
inferred← citeshttps://doi.org/10.3390/biology10111158openalex-snapshot
Effect of Serial Passage on the Pathogenicity and Immunogenicity of Vaccinia Virus LC16m8 Strain
inferred← citeshttps://doi.org/10.3390/biomedicines9091122openalex-snapshot
Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
inferred← citeshttps://doi.org/10.3390/ijerph20042963openalex-snapshot
Safety and Efficacy of Post-Eradication Smallpox Vaccine as an Mpox Vaccine: A Systematic Review with Meta-Analysis
inferred← citeshttps://doi.org/10.3390/ijms26031203openalex-snapshot
Elucidating the Mechanism of VVTT Infection Through Machine Learning and Transcriptome Analysis
inferred← citeshttps://doi.org/10.3390/microorganisms11112713openalex-snapshot
A Review of the Past, Present, and Future of the Monkeypox Virus: Challenges, Opportunities, and Lessons from COVID-19 for Global Health Security
showing the first 200 of 245 · page through all 245
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.